16:06 EDT Spruce Biosciences says Phase CAH study missed efficacy endpoint
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRB:
- SPRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Three new option listings on February 27th
- Spruce Biosciences price target raised to $9 from $8 at RBC Capital
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim
